VCYT — Veracyte Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $33.51
- 30-Day Move
- -21.8%
- Market Cap
- $2.6B
- Shares Outstanding
- 79,460,000
- P/E Ratio
- 39.71
- P/B Ratio
- 2.54
Veracyte Inc
A read-only Alphactor snapshot forVeracyte Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$33.51
30-Day Move
-21.8%
Market Cap
$2.6B
Shares Outstanding
79,460,000
P/E Ratio
39.71
P/B Ratio
2.54
$33.51
-21.8%last 90 delayed daily bars
90D High
$46.76
90D Low
$29.45
Avg Volume
847,808
Gross margin is running at 70.1%, which gives a quick read on operating quality before you open the full model.
Net margin is 12.8%, useful for comparing VCYT against peers in Biotechnology.
VCYT is down 21.8% over the last 30 trading days shown on this page.
Latest operating income is $40M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$31.39
Rule of 40
40.5%
Dark Pool Short %
52.6%
Latest Close
$33.51
30-Day Move
-21.8%
Market Cap
$2.6B
Shares Outstanding
79,460,000
P/E Ratio
39.71
P/B Ratio
2.54
ROE
5.1%
ROA
4.7%
Gross Margin
70.1%
Operating Margin
11.2%
Net Margin
12.8%
Debt / Equity
0
Current Ratio
8.15
Latest Revenue
$141M
Revenue
$141M
Gross Profit
$102M
Operating Income
$40M
Net Income
$41M
Gross Margin
7010.0%
Net Margin
1283.0%
Current Ratio
8.15
Debt / Equity
0.00
Fair Value
$31.39
Upside / Downside
-6.3%
Signal
Fairly Valued
Implied Growth
4.9%
DCF
$53.09
EPV
$4.46
EV/Rev
$36.61
Growth Assumption
20.4%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$127M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Altman Z
16.81
Safe
Piotroski
8
Strong (7-9)
Cash Conversion
2.05x
Rule of 40
40.5%
Strong
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $297M | $-35M | $-37M | $-1M |
| 2023-12-31 | $361M | $-17M | $-74M | $34M |
| 2024-12-31 | $446M | $20M | $24M | $64M |
| 2025-12-31 | $517M | $78M | $66M | $127M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Buy Value
$0
Sell Value
$11M
Buys
0
Sells
42
Buy Value
$0
Sell Value
$11M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-10 | Haas Kevin Richard | A | 44,221 | $0.00 |
| 2026-03-06 | Leite John | A | 6,578 | $0.00 |
| 2026-03-06 | Leite John | A | 36,181 | $0.00 |
| 2026-03-06 | McGuire Annie | A | 26,314 | $0.00 |
| 2026-03-06 | McGuire Annie | A | 32,892 | $0.00 |
| 2026-03-06 | Chambers Rebecca | A | 13,157 | $0.00 |
| 2026-03-06 | Chambers Rebecca | A | 36,181 | $0.00 |
| 2026-03-06 | Febbo Phillip G. | A | 6,578 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 4,789,519 | 0.06% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,481,526 | 0.03% | 2025-12-31 |
| ARK ETF Trust-ARK Innovation ETF | 2,064,131 | 0.03% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2,048,617 | 0.03% | 2026-03-31 |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 1,935,317 | 0.02% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 1,911,923 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1,792,922 | 0.02% | 2025-12-31 |
| Vanguard Explorer Fund | 1,476,726 | 0.02% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2026-02-17
--
--
D.E. Shaw
Filed 2026-02-17
--
--
Two Sigma Advisers
Filed 2025-05-15
--
--
Vanguard Group
Filed 2026-01-29
$358M
-0.0%
FMR LLC (Fidelity)
Filed 2026-02-17
$242M
-15.6%
BlackRock
Filed 2024-08-13
$169M
--
ARK Investment Management
Filed 2026-02-11
$164M
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.